Skip to main content
Clinical Trials/NCT06708507
NCT06708507RecruitingNot Applicable

A Prospective Study on the Correlation Between Tissue-resident Immune Cell Subsets and Graft-versus-host Disease Following Hematopoietic Stem Cell Transplantation.

Nanfang Hospital, Southern Medical University1 site in 1 country40 target enrollmentStarted: November 16, 2024Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
40
Locations
1
Primary Endpoint
Association between tissue-resident Immune cell subsets in organ and acute graft-vs-host disease (aGVHD) outcomes.

Study Overview

Brief Summary

This is a prospective study investigating the role of tissue-resident immune cell subsets in the occurrence and progression of graft-versus-host disease following hematopoietic stem cell transplantation. Approximately 40 subjects(including 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients ).

Detailed Description

This study was a single-center, observational, prospective cohort study. The study lasted for 3 months, from 2024.11 to 2025.02.It is planned to enroll 40 subjects, divided into 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients. No randomization or any protocol-driven treatment will be performed or provided to subjects during the course of the study. Treatment decisions and selection of treatment options are left to the discretion of the treating physician, if clinically appropriate. All recipients will be followed for aGVHD evaluation,overall survival(OS) ,disease-free survival (DFS). aGVHD were graded according to published guidelines. All recipients will be monitored every month until the study is completed.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Voluntarily sign the informed consent form;
  • Age 16-65 years old
  • Clinically diagnosed with GVHD for the first time/receiving GVHD treatment.

Exclusion Criteria

  • Have a history of other tumors
  • With poor compliance or mental disorders
  • Infected with HIV and HCV
  • With uncontrolled HBV infection
  • With other autoimmune diseases
  • Those who are judged by the researcher to be unsuitable to participate in this study

Outcomes

Primary Outcomes

Association between tissue-resident Immune cell subsets in organ and acute graft-vs-host disease (aGVHD) outcomes.

Time Frame: 100days

Measure the number/proportion of resident T,B and macrophage cell subsets in the main organ of aGVHD(skin,intestine and liver).

Secondary Outcomes

  • Association between tissue-resident Immune cell subsets in organ and overall survival(OS).(100days)
  • Association between tissue-resident Immune cell subsets in organ and disease-free survival (DFS)(100days)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials